Rituximab Offlabel denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for rituximab offlabel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied This Rituximab Claim: Quantity Limits

A quantity-limit denial means BCBS has approved rituximab for your condition but has capped the amount it will cover — typically expressed as a maximum number of infusions, cycles, or doses within a defined time period. The quantity your prescriber ordered exceeds what BCBS's policy allows without additional authorization.

For off-label rituximab, quantity limits are often set based on the dosing schedule studied or used for the on-label indication, which may differ from the schedule appropriate for your specific off-label condition. When the prescribed regimen reflects your prescriber's clinical judgment and the applicable specialty-society guidance, a quantity-limit denial is typically appealable on medical-necessity grounds.

## Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (job-based plans) you are entitled to a full-and-fair review and access to the quantity-limit criteria applied. File within the window stated on your denial letter.
• External review: Under ACA §2719, IRO review is available after internal appeals are exhausted, generally within four months of the final internal denial.
• Expedited option: Request simultaneously with the standard appeal if a delay in treatment would worsen your health.

## Documentation to Gather

1. Diagnosis confirmation — full specialist records establishing the diagnosis and its current status or disease activity. 2. Prescriber dosing rationale letter — your physician should explain the clinical basis for the prescribed quantity, citing the applicable specialty-society guideline organization (not specific numeric protocol details, which are in the full guideline document) and the reason your case requires this schedule. 3. Treatment response documentation — if prior cycles have been administered, include documentation of response, disease course, and the clinical reason continued or repeat dosing is necessary. 4. Clinical severity documentation — current chart notes showing disease activity, organ involvement, or functional status that supports the need for the prescribed quantity. 5. BCBS quantity-limit policy — obtain the exact text of the quantity-limit provision so your appeal addresses each stated criterion.

## Criteria-Mapping Structure

For each quantity-limit criterion in BCBS's policy, your prescriber's letter should provide a specific, chart-based answer. For example: if the policy limits coverage to a defined number of cycles per year without documented disease progression, the letter should cite the chart note establishing progression. Map criterion to chart fact, one by one, in the same order the policy presents them.